BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) — Genetron Holdings Restricted (“Genetron Well being” or the “Firm”, Nasdaq: GTH), a number one precision oncology platform firm in China that focuses on providing molecular profiling checks, in the present day introduced its participation within the launch of a serious nationwide analysis mission for early screening of lung and digestive system cancers led by China’s Ministry of Science and Expertise (“MOST”).
Based mostly on the Firm’s proprietary know-how, Mutation CapsuleTM, Genetron Well being is collaborating with the Nationwide Most cancers Middle and the Most cancers Hospital, Chinese language Academy of Medical Sciences (“CAMS”) for the second time, to offer key technological contributions for the “Liquid Biopsy-based Malignant Tumor Early Screening Expertise Analysis and Improvement Undertaking”. The launch assembly for the mission was held in Beijing on August 29.
On the assembly, representing Genetron Well being was Sizhen Wang, the Firm’s co-founder and CEO. Different attendees on the occasion included Jie He, Academician of Chinese language Academy of Sciences, Director of Nationwide Most cancers Middle and President of Most cancers Hospital, CAMS; Jie Wang, Director of Division of Oncology, Most cancers Hospital, CAMS; and Qian Liu, professor on the Most cancers Hospital, CAMS.
The mission’s purpose is to realize a breakthrough in the important thing applied sciences of liquid biopsy for most cancers screening. Beneath this premise, the mission targets to construct a extremely delicate, extremely particular, environment friendly and reasonably priced liquid biopsy-based early detection know-how platform, and develop proprietary most cancers screening and early detection checks. The mission will concentrate on lung and digestive system cancers, and is designed to incorporate a multi-center, potential cohort examine in lung most cancers of 120,000 high-risk people in 20 provinces, in addition to a cohort examine in digestive system most cancers of greater than 100,000 sufferers in city areas in China. At present, Genetron Well being is the one firm in China taking part in nationwide key analysis and growth initiatives organized by the Ministry of Science and Expertise for liver, lung and digestive most cancers early screening.
“Most cancers has develop into the main explanation for dying in China and is a severe menace to individuals’s well being and lives, but most sufferers who search therapy are already at a terminal stage,” mentioned Jie He. “The 2019 authorities work report expresses the necessity to promote early screening, early detection and therapy, and scientific analysis on cancers, aiming at fixing this vital downside of individuals’s livelihood. The launch of this mission signifies that preventative screening and early detection of cancers has develop into a serious analysis and growth course for the Ministry of Science and Expertise, and it is usually a part of the nationwide technique. We hope to extend the depth, prevalence and practicability of most cancers early screening, early detection and therapy analysis to profit most cancers sufferers.”
“Early detection and therapy are the simplest methods to enhance medical outcomes in most cancers sufferers. We select to accomplice with Genetron Well being for its main know-how capabilities and we count on to develop a proprietary malignant tumor screening and early detection testing equipment and implement into medical use to considerably enhance the remedy charges of a majority of these most cancers for our residents,” mentioned Jie Wang.
“The significance of early most cancers screening can’t be overemphasized. Nonetheless, present examinations lack exact and high-quality tumor screenings and solely use a single biomarker goal. Early most cancers prognosis and screening usually doesn’t meet the usual of specificity and sensitivity, which is able to mislead sufferers. With this nationwide analysis mission, we hope to realize know-how breakthroughs and transfer previous the challenges of present medical screenings,” mentioned Qian Liu.
Genetron Well being, as a number one innovator within the subject of early most cancers screening in China, plans to undertake its self-developed Mutation CapsuleTM know-how for this mission. Mutation CapsuleTM requires solely a small quantity of blood to concurrently detect methylation and a number of other forms of ctDNA alternations together with SNV, Indel, CNV, and many others. This can permit a number of checks to be carried out on one pattern with out sacrificing sensitivity. The Mutation Capsule know-how has proven excessive sensitivity and specificity preliminary information within the early screening examine of liver most cancers.
“We’re honored to be concerned on this main government-led mission primarily based on our Mutation CapsuleTM know-how, which highlights our technological energy in most cancers early screening. As well as, we’re delighted that we’re in a position to apply this know-how past liver most cancers and now into lung and digestive system cancers,” mentioned Sizhen Wang. “We’ll proceed to develop our early screening analysis into extra forms of most cancers and to speed up the medical growth and commercialization effort. Our purpose is to develop checks with excessive efficiency and reasonably priced pricing with a purpose to cut back cancer-related healthcare bills in our nation, and extra importantly, to avoid wasting extra lives.”
About Genetron Well being Early Screening for Liver Most cancers
In March 2019, Genetron Well being, in collaboration with the Nationwide Most cancers Middle and the Most cancers Hospital, CAMS, deployed Mutation CapsuleTM know-how to finish a potential cohort examine in liver most cancers early screening (the HCCscreenTM) on hepatitis B virus carriers utilizing cell free DNA (cfDNA) and protein markers. Outcomes had been revealed in Proceedings of the Nationwide Academy of Sciences (PNAS), cited within the Tips for Analysis and Remedy of Major Liver Most cancers (2019 version) issued by the Nationwide Well being Fee, and Genetron Well being was accredited to hitch a Main Nationwide Science and Expertise Undertaking by MOST.
Genetron Well being has since continued to optimize the Mutation CapsuleTM platform and liver early screening take a look at in its ongoing cohort examine with 4,500 HBsAg+ people. Preliminary information from 297 sufferers at one heart demonstrated over 92% sensitivity, 93% specificity and a 35% optimistic predictive worth.
About Genetron Holdings Restricted
Genetron Holdings Restricted (“Genetron Well being” or the “Firm”) (Nasdaq:GTH)is a number one precision oncology platform firm in China that focuses on most cancers molecular profiling and harnesses superior applied sciences in molecular biology and information science to remodel most cancers therapy. The Firm has developed a complete oncology portfolio that covers all the spectrum of most cancers administration, addressing wants and challenges from early screening, prognosis and therapy suggestions, in addition to steady illness monitoring and care. Genetron Well being additionally companions with international biopharmaceutical corporations and presents personalized providers and merchandise. For extra info, please go to ir.genetronhealth.com.
Secure Harbor Assertion
This press launch accommodates forward-looking statements throughout the that means of federal securities legal guidelines, together with statements relating to the potential advantages and benefits of Genetron Well being’s Mutation Capsule™ know-how, which contain dangers and uncertainties that would trigger the precise outcomes to vary materially from the anticipated outcomes and expectations expressed in these forward-looking statements. These statements are made below the “secure harbor” provisions of the U.S. Non-public Securities Litigation Reform Act of 1995. Statements that aren’t historic details, together with statements in regards to the Firm’s beliefs and expectations, are forward-looking statements. Ahead-looking statements contain inherent dangers and uncertainties, and a variety of components might trigger precise outcomes to vary materially from these contained in any forward-looking assertion. In some instances, forward-looking statements may be recognized by phrases or phrases corresponding to “could”, “will,” “count on,” “anticipate,” “goal,” “intention,” “estimate,” “intend,” “plan,” “consider,” “potential,” “proceed,” “is/are more likely to” or different related expressions. Additional info relating to these and different dangers, uncertainties or components is included within the Firm’s filings with the SEC. All info supplied on this press launch is as of the date of this press launch, and the Firm doesn’t undertake any responsibility to replace such info, besides as required below relevant legislation.
Investor Relations Contacts
Head of Investor Relations
Electronic mail: [email protected]
Cellphone: +1 (408) 204-5343
Westwicke, an ICR Firm
Electronic mail: [email protected]
Cellphone: +1 (646) 277-1282